Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 8/20 | 1.00 |
| ▸ | MIF | P14174 | 2/20 | 0.74 |
| ▸ | RAB9A | P51151 | 7/20 | 0.72 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.72 |
| ▸ | NPC1 | O15118 | 5/20 | 0.72 |
| ▸ | RECQL | P46063 | 1/20 | 0.72 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.64 |
| ▸ | LMNA | P02545 | 2/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.56 |
| ▸ | MEN1 | O00255 | 2/20 | 0.53 |
| ▸ | PKM | P14618 | 1/20 | 0.53 |
| ▸ | MITF | O75030 | 1/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.53 |
| ▸ | HPGD | P15428 | 1/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.49 |
| ▸ | ESRRG | P62508 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8471959 | 0.90 | MAPT (0.81) | MAPTMIFRAB9ASMN1; SMN2NPC1 | |
| SCHEMBL6423387 | 0.86 | MAPT (0.76) | MAPTMIFRAB9ASMN1; SMN2NPC1 | |
| SCHEMBL3266677 | 0.86 | MAPT (0.76) | MAPTMIFRAB9ASMN1; SMN2NPC1 | |
| SCHEMBL12979794 | 0.86 | MAPT (0.76) | MAPTMIFRAB9ASMN1; SMN2NPC1 | |
| SCHEMBL13401232 | 0.85 | MIF (0.78) | MAPTMIFRAB9ASMN1; SMN2NPC1 | |
| SCHEMBL6444640 | 0.85 | MIF (1.00) | MAPTMIFRAB9ASMN1; SMN2NPC1 | |
| SCHEMBL6444643 | 0.85 | MIF (1.00) | MAPTMIFRAB9ASMN1; SMN2NPC1 | |
| SCHEMBL6444624 | 0.84 | MAPT (0.72) | MAPTMIFRAB9ASMN1; SMN2NPC1 | |
| SCHEMBL17290220 | 0.84 | MIF (0.76) | MAPTMIFRAB9ASMN1; SMN2NPC1 | |
| SCHEMBL5373502 | 0.84 | MIF (0.76) | MAPTMIFRAB9ASMN1; SMN2NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1244660-B1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF PAIN | ASTRAZENECA AB (SE) | 2006-03-22 | — | — | EP | disclosed |
| US-20030181449-A1 | Methods and compositions for the treatment of pain | ASTRAZENCA AB (SE) | 2003-09-25 | — | — | US | disclosed |
| EP-1244660-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF PAIN | AstraZeneca AB (SE) | 2002-10-02 | — | — | EP | disclosed |
| WO-2001047924-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF PAIN | ASTRAZENECA AB (SE) | 2001-07-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030181449-A1 | Methods and compositions for the treatment of pain | OPRK1, ACHE, OPRD1 | MAPT 2472/4885MIF 2996/4885RAB9A 3020/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.